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patients with and without immobilization were 0.39 ± 0.34 
mm and 0.71 ± 0.75 mm, respectively (p<0.001, t-test).  
 
 
Conclusions: During spine SABR, large inter- and intrafraction 
motion of ≥ 3mm and/or ≥ 3° is uncommon. The use of a 
vacuum mattress improves the intrafraction setup accuracy in 
particular, but also the interfraction setup accuracy 
regarding setup errors ≥ 2°. A 6D couch positioning correction 
may further increase setup accuracy. 
   
 
Poster: Physics track: Radiation protection, out-of-field 
dosimetry and secondary cancer induction  
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Purpose/Objective: The risk of second tumor induced by 
radiotherapy treatments is an issue addressed in long survival 
patients. Prostate radiotherapy represents a critical scenario 
considering the increase of target dose and irradiated volume 
with IMRT approaches and the decrease of mean age of 
patients. The goal of this study was to evaluate the impact of 
modern rotational IMRT techniques in the risk of second 
tumor induction for prostate patients in age classes from 50 
to over 70.  
Materials and Methods: Based on both consolidated models 
(BEIR VII and Shuriak age dependent organ risk coefficients) 
and doses to the critical organs, the Lifetime Attributable 
Risk (LAR) for second tumor induction was calculated 
simulating small field (prostate+seminal vesicles) and large 
field (whole pelvis,WP) for Helical Tomotherapy (HT) and 
Rapid Arc (RA), according to our clinical protocol of moderate 
hypofractionation (71.4Gy in 28 fr) and concomitant 
irradiation of WP to 51.8Gy for intermediate/high risk 
patients. Due to the lack of calculation algorithms in 
Treatment Planning Systems (TPS) where leakage and 
internal radiation scattering are unreliable at large distance 
from target, the doses to the critical organs outside the 
treatment volume were measured with termoluminescent 
dosemeters (TLD) in an anthropomorphic phantom. Whereas, 
doses to the organs closest to the treatment volume, as 
bladder, rectum, colon, bone marrow, were derived from TPS 
data. Doses from IGRT procedures were also assessed based 
on phantom measurements.  
Results: The LAR values for all organs are reported in the 
Table. For small field in the oldest age class the evaluated 
LAR, 2%, agree with literature data confirming the robustness 
of our estimate methods. LAR values increase by a factor of 
approximately 3 as age decreases from 70 to 50s. WP 
irradiation translates in a LAR increase of a factor 2, with 
corresponding absolute values around 10-13% for ages 50-60s. 
No differences were found between RA and HT. Bladder and 
rectum cancer and leukemia represent almost the totality of 
risk for second tumor induction with small fields, whereas, a 
significant risk for colon tumor induction is added in large 
pelvic irradiation with LAR values comparable to bladder. 
IGRT adds a minor, although non-negligible, contribution to 
the risk (0,2-0,6%) if daily set-up verification and high 
resolution modality is included. 
 
 
Conclusions: As prostate cancer is detected earlier the 
probability of an increase in early stage, young patients rises, 
and life expectancy thus increases. Radiotherapy improved 
the tailoring of the dose around the target at the cost of a 
greater dose to surrounding organs, so increasing the risk of 
second tumor induction, especially for patients expected to 
reach a survival of 15 years or more. The increased risk 
induced by lower age and larger volumes should be 
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considered when choosing this therapeutic approach for 
younger patients.  
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Purpose/Objective: Measuring, calculating, and reducing 
non-target doses present unique challenges with which many 
medical physicists may have limited experience. The 
American Association of Physicists in Medicine Task Group 
(TG) 158 report: 'Measurement and calculation of doses 
outside the treatment volume from external-beam radiation 
therapy' provides guidance for physicists in assessing and 
managing non-target doses. The primary objectives of this 
presentation are to (1) highlight major concerns with non-
target radiation, (2) provide a rough estimate of doses 
associated with different treatment approaches in clinical 
practice, and (3) to highlight techniques that may be 
considered for reducing non-target doses and (4) summarize 
TG-158 recommendations for both clinical and research 
practice. 
Materials and Methods: The TG-158 report reviewed 
approximately 300 publications in the literature to provide 
guidance on management of non-target doses. This 
presentation will summarize key components of the report 
and its recommendations.  
Results: The Task Group 158 report generated guidance for 
physicists in terms of doses to non-target structures, 
dosimetry and computational techniques for assessing non-
target doses, as well as potential treatment and patient 
management options for minimizing non-target doses. This 
was done by addressing the following charges: 
1. Highlight major concerns with non-target radiation 
2. Provide a rough estimate of doses associated with 
different treatment approaches in clinical practice 
3. Discuss the uses of dosimeters and phantoms for measuring 
photon, electron, and neutron exposures  
4. Discuss the use of calculation techniques (including Monte 
Carlo) for dosimetric evaluations 
5. Highlight techniques that may be considered for reducing 
non-target doses 
6. Make recommendations for clinical and research practice 
This presentation will summarize the Task Group report’s 
findings on topics 1, 2, 5, and 6 from the list above. Topics 3 
and 4, measurement and calculation of non-target doses, are 
each broad topics and separate abstracts detailing these 
topics are separate submitted abstracts at this meeting. 
Conclusions: This presentation will summarize key 
components of the AAPM TG-158 report and its 
recommendations.  
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Purpose/Objective: The literature has reported that some 
TPSs underestimate the dose outside the radiation field edge 
(out-of-field). Sources of out-of-field dose are phantom 
scatter, head scatter and head and MLC leakage and 
transmission. The issues associated with inaccurate out-of-
field dose reporting is with secondary cancer risk estimation, 
incorrect clinical decisions based on inaccurate OAR doses, 
incorrect estimation of dose to implanted devices and 
pregnant patients, etc. The aim of this study was to 
understand how different detectors respond to out-of-field 
radiation and compare measurements to Monte Carlo (MC). 
Materials and Methods: Profiles extending ~20 cm outside 
the radiation field edge and divergent out-of-field PDDs were 
acquired with a range of clinically available detectors (PTW 
microDiamond, EDiode, Pinpoint and SRS Diode) using a PTW 
MP3 Watertank for a 10x10cm2 field and 90cm SSD on an 
Elekta Precise linac operating at 6MV. X, Y and diagonal 
profiles were acquired at depths of dmax, 5, 10, 15 and 
20cm. Divergent PDDs were acquired at 1,2,3,4,5,7,10 and 15 
cm from the field edge using in-house software to correct for 
daily beam inclination changes. A MC linac model was 
created in BEAMnrc and dose calculations were performed 
using DOSXYZnrc.  
Results: All profiles were normalised to their respective CAX 
dose and agreed to within 0.5% at depths of dmax and 5cm 
and within 1% at depths between 5 and 20cm. Comparison of 
the measured out-of-field profiles to MC reveals agreement 
to within 1%. The SRS diode deviates from both MC and the 
other detectors at depths greater than 5 cm better 
agreement is observed at shallower depths. 
All divergent PDDs were normalised to their respective 
average dose. The divergent PDDs (Fig. 1) display an initial 
build-up and down portion followed by a second smaller 
build-up region for PDDs acquired at 1-10cm from the field 
edge.  
